Lifestyle Medicine and Menopause in Viet Nam: Symptom Management, Long-Term Health, and the Limits of Lifestyle Interventions

Lifestyle Medicine and Menopause in Viet Nam: Symptom Management, Long-Term Health, and the Limits of Lifestyle Interventions

Primary category: Evidence & Clinical Practice
Secondary category: Lifestyle Medicine in Viet Nam
Article type: VLMA Perspective
Last reviewed: October 30, 2026

Consider a woman in her early fifties who has started waking several times a night because of hot flashes. She feels tired during the day, finds it harder to concentrate at work, and wonders whether menopause is affecting her health. After reading about the benefits of healthy living, she becomes more physically active, improves her diet, and makes an effort to manage stress. These changes may benefit her health, but her night sweats continue to disrupt her sleep.

Another woman of a similar age has few noticeable menopausal symptoms. She is more concerned about osteoporosis, cardiovascular health, and changes in body composition. A third experiences irregular bleeding or persistent vaginal discomfort and needs clinical assessment rather than general lifestyle advice alone.

These women are going through a similar stage of life, but their healthcare needs are different. Menopause is not a single clinical problem, and no one approach addresses every symptom or long-term health concern.

Lifestyle Medicine has a role during this transition. Appropriate nutrition, physical activity, restorative sleep, stress management, avoidance of risky substances, positive social connections, and evidence-based behavior change can support health and well-being. However, an intervention that benefits long-term health is not necessarily an effective treatment for a particular menopausal symptom.

For the Vietnam Lifestyle Medicine Alliance (VLMA), this distinction is important. As a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited, VLMA seeks to advance evidence-based Lifestyle Medicine through professional education, scientific knowledge exchange, capability development, and collaboration.

Menopause provides an opportunity to examine where Lifestyle Medicine can contribute, where the evidence remains uncertain, and when specific medical treatments or further clinical assessment are necessary.

Understanding Menopause and Its Clinical Variability

Menopause is a natural biological transition associated with declining ovarian follicular function and estrogen production. According to the World Health Organization, natural menopause generally occurs between the ages of 45 and 55. It is usually recognized retrospectively after 12 consecutive months without menstruation, provided there is no other physiological or pathological explanation and no medical intervention responsible for the absence of menstruation.

Perimenopause refers to the transition surrounding menopause, beginning when menstrual changes or other signs of the transition first appear and extending until one year after the final menstrual period. During this time, hormone levels fluctuate, menstrual cycles may become irregular, and symptoms such as hot flashes, night sweats, sleep disturbance, and vaginal dryness may develop.

Not every woman experiences these symptoms, and their severity and duration vary considerably. Some women have relatively few difficulties, while others experience symptoms that interfere with work, sleep, relationships, or daily activities. The experience can also change over time, with some symptoms improving while others persist into postmenopause.

Menopause itself should not automatically be treated as a disease requiring medication. Equally, symptoms that substantially affect quality of life should not be dismissed as an unavoidable part of aging.

The European Society of Endocrinology's 2025 clinical practice guideline emphasizes individualized assessment across perimenopause and postmenopause. For women aged 45 or older with typical symptoms and menstrual changes, menopause can often be identified clinically without routine hormone testing. Further investigation may be appropriate when the presentation is atypical, menopause occurs earlier than expected, or another condition is suspected.

This matters because fatigue, sleep disturbance, mood changes, palpitations, and changes in body weight do not necessarily result from menopause. Thyroid disorders, anemia, depression, medication effects, sleep disorders, and other medical conditions may produce overlapping symptoms.

Clinical assessment should therefore consider more than whether a woman has entered menopause. It should establish which concerns affect her life, whether another condition requires attention, and which interventions are appropriate for her circumstances.

The Clinical Context in Viet Nam

An important consideration for healthcare professionals in Viet Nam is that menopause care is already addressed in dedicated national professional guidance.

On December 30, 2024, the Ministry of Health issued Decision No. 3977/QĐ-BYT, promulgating the National Guidelines for Reproductive Health Care Services: Health Care for Women During Perimenopause and Menopause. The decision took effect on the date of issuance, applies to medical examination and treatment facilities throughout Viet Nam, and replaced Decision No. 3793/QĐ-BYT dated December 17, 2024.

The document addresses the physiological changes associated with menopause, common symptoms and their management, menopausal hormone therapy, counseling, and preventive healthcare. It also discusses nutrition, physical activity, psychological well-being, osteoporosis, cardiometabolic risks, sexual health, and circumstances requiring specialist assessment.

This national guidance provides a foundation for discussing Lifestyle Medicine in women's midlife health. It also means that international recommendations should be interpreted alongside Vietnamese professional requirements rather than presented as substitutes for them.

Some differences between Vietnamese guidance and international recommendations are particularly relevant. These concern the strength of evidence for certain complementary approaches and the selection of menopausal hormone therapy in women with specific medical conditions.

A treatment may be included as a supportive option in one guideline while another professional body considers the evidence insufficient to recommend it for a particular symptom. Similarly, an international position paper may discuss treatment possibilities that differ from contraindications listed in existing Vietnamese guidance.

These differences should be acknowledged rather than overlooked. Healthcare professionals need to understand both the scientific evidence and the clinical and regulatory framework applicable to their practice.

What Lifestyle Medicine Can Contribute to Women's Midlife Health

The menopausal transition often occurs during a period when cardiovascular, metabolic, musculoskeletal, and other health risks become increasingly relevant. Changes in body composition, fat distribution, sleep, and physical function may occur, although these reflect the combined effects of aging, hormonal changes, existing health conditions, medications, genetics, and behavior.

Lifestyle Medicine can contribute by addressing modifiable risk factors and supporting behaviors with established health benefits.

Regular physical activity supports cardiovascular fitness, metabolic health, muscle strength, and physical function. Resistance training is particularly relevant to maintaining strength and mobility as women age, while appropriate weight-bearing activity and balance exercises contribute to musculoskeletal health and reducing fall risk. Exercise recommendations should reflect individual health, physical capacity, preferences, and clinical limitations.

Nutrition is equally important. A balanced, plant-predominant dietary pattern incorporating vegetables, fruits, whole grains, legumes, suitable protein sources, and healthy fats can support cardiometabolic health and nutritional adequacy. Attention to protein intake, calcium, and vitamin D may also be relevant to bone and muscle health. Supplementation, however, should reflect dietary intake, nutritional status, clinical circumstances, and applicable professional guidance rather than being recommended indiscriminately.

Restorative sleep, tobacco avoidance, reducing harmful alcohol consumption, appropriate stress management, and meaningful social relationships can also support physical and psychological well-being during midlife.

These approaches are consistent with the broader principles of evidence-based Lifestyle Medicine and the International Menopause Society's recommendations on women's midlife health and menopause, initially published in December 2025 and updated through its professional resources in March 2026.

What matters is understanding the outcome an intervention is expected to improve.

A woman who becomes more physically active may improve her cardiovascular fitness and muscle strength while continuing to experience frequent night sweats. Another may improve the quality of her diet without noticing a meaningful change in vaginal dryness or other menopausal symptoms.

The absence of symptom relief does not mean those lifestyle changes were unsuccessful. Their value should be assessed against the health outcomes they are intended to influence.

Problems arise when established benefits for general health are presented as proof that the same intervention can treat every menopausal symptom.

Hot Flashes and Night Sweats: When Lifestyle Advice Is Not Enough

Hot flashes and night sweats, collectively known as vasomotor symptoms, are among the most recognizable manifestations of menopause. For some women, they are relatively mild. For others, repeated episodes disrupt sleep, affect concentration, and interfere with everyday functioning.

Exercise, yoga, dietary changes, mindfulness, and relaxation are often suggested for menopausal symptoms. These approaches may support general health or well-being, but the evidence for reliably reducing vasomotor symptoms is more limited.

The Menopause Society's 2023 position statement on nonhormonal treatment reviewed a range of lifestyle, psychological, pharmacological, and complementary interventions. It did not recommend exercise, yoga, mindfulness-based interventions, relaxation techniques, dietary modification, or herbal supplements as established treatments specifically for hot flashes and night sweats because the available evidence did not demonstrate sufficiently reliable effectiveness for those outcomes.

This should not be interpreted as a recommendation against physical activity or stress management. A woman may still benefit from regular exercise, yoga, or relaxation. The narrower question is whether these approaches can be expected to reduce the frequency or severity of vasomotor symptoms.

The same evidence review identified weight loss as a potentially helpful intervention for reducing vasomotor symptoms, although the supporting evidence is less robust than that for established medical treatments. Weight management should be individualized and should not be promoted as a universal solution, particularly when a woman has nutritional concerns, unintended weight loss, or other relevant medical conditions.

For women with bothersome vasomotor symptoms, systemic menopausal hormone therapy remains the most effective established treatment when appropriately indicated. Its use requires individualized assessment of symptoms, benefits, risks, contraindications, and patient preferences.

When hormone therapy is contraindicated, unsuitable, or declined, evidence-based nonhormonal options may be considered. These include selected prescription medicines, menopause-specific cognitive behavioral therapy, and clinical hypnosis where appropriately trained practitioners and suitable services are available.

Menopause-specific cognitive behavioral therapy can help reduce the distress and interference associated with vasomotor symptoms and improve how women cope with their effects on daily life. However, improvements in perceived symptom burden should not automatically be interpreted as a consistent reduction in the actual number of hot flashes.

Nonhormonal medication options have also evolved. Fezolinetant and elinzanetant are examples of newer medicines that target neurokinin signaling pathways involved in thermoregulation. In March 2026, the United Kingdom's National Institute for Health and Care Excellence recommended fezolinetant as an option for moderate to severe menopausal vasomotor symptoms when hormone therapy is unsuitable. Elinzanetant received United States Food and Drug Administration approval in October 2025.

These developments do not establish that the medicines are authorized or routinely available in Viet Nam. Their local regulatory status, approved indications, contraindications, safety requirements, and availability must be verified before clinical use.

Safety remains important even for nonhormonal treatments. Fezolinetant, for example, has been associated with rare but serious liver injury, prompting a boxed warning and specific liver function monitoring requirements from the United States Food and Drug Administration.

The broader message is that troublesome menopausal symptoms deserve appropriate assessment and access to treatments supported by evidence. Women should not be expected to tolerate substantial symptoms simply because they have already been advised to live more healthily.

Sleep, Mood, and Everyday Functioning

Sleep problems are common during the menopausal transition, but they do not all have the same cause. Night sweats may repeatedly interrupt sleep, while some women experience insomnia independently of vasomotor symptoms. Anxiety, depression, chronic pain, obstructive sleep apnea, medications, and other medical conditions may also contribute.

This makes it important to understand the reason for poor sleep before recommending treatment. General advice about sleep routines may help some women, but it is not necessarily sufficient for persistent insomnia or sleep disturbance caused by another condition.

A woman whose sleep is repeatedly interrupted by night sweats may benefit from appropriate treatment of vasomotor symptoms. Someone with chronic insomnia may require cognitive behavioral therapy for insomnia, while suspected obstructive sleep apnea calls for a different diagnostic and management approach.

The National Institute for Health and Care Excellence also recognizes menopause-specific cognitive behavioral therapy as an option for sleep problems associated with menopausal vasomotor symptoms.

Mood changes require similar care. Some women experience irritability, anxiety, or low mood during perimenopause, and hormonal fluctuations may contribute. However, persistent depressive symptoms, significant anxiety, or impaired functioning should not automatically be attributed to menopause.

Physical activity, sleep support, stress management, and positive social connections can contribute to psychological well-being. They should not replace appropriate mental health assessment or treatment when a mental health condition is suspected.

The appropriate response depends on the underlying problem. Two women may describe poor sleep or low mood but require different forms of care.

Genitourinary Symptoms and Sexual Health Require Specific Attention

Vaginal dryness, discomfort during sexual activity, urinary urgency, and other genitourinary symptoms may develop during and after menopause. Some of these concerns are associated with the genitourinary syndrome of menopause, which involves changes in vulvovaginal and lower urinary tract tissues related to declining estrogen levels.

Unlike vasomotor symptoms, which may lessen over time, genitourinary symptoms can persist or become more troublesome without appropriate management.

General advice about nutrition, exercise, or stress management is not a substitute for symptom-directed care. Nonhormonal vaginal moisturizers and lubricants may provide relief for some women. Locally administered vaginal estrogen is an established treatment option for appropriately selected patients and differs from systemic hormone therapy in its intended effects and degree of systemic absorption.

The National Institute for Health and Care Excellence recommends offering vaginal estrogen for genitourinary symptoms in people without a personal history of breast cancer, with individualized treatment selection and appropriate review.

For women with a history of breast cancer, treatment decisions are more complex. Nonhormonal approaches are generally considered first, while persistent symptoms may warrant specialist discussion. Particular care is needed for women receiving endocrine treatment for breast cancer, including aromatase inhibitors.

These international recommendations must be interpreted alongside Vietnamese professional guidance and the authorized use of relevant medicines.

Not every vaginal or urinary symptom is caused by menopause. Infection, dermatological conditions, pelvic floor disorders, and other medical problems may produce similar symptoms. Persistent pain, abnormal bleeding, recurrent urinary symptoms, or other concerning findings require appropriate clinical assessment.

Sexual health should also be discussed respectfully and without assumptions. Some women experience reduced sexual desire or discomfort, while others do not. Relationship circumstances, medications, emotional well-being, underlying disease, and personal preferences may influence sexual functioning.

Care should respond to the woman's concerns rather than assume that menopause necessarily causes sexual dysfunction or that every woman seeks the same treatment outcome.

Menopausal Hormone Therapy: Individual Benefits, Risks, and Clinical Boundaries

Menopausal hormone therapy is sometimes discussed as though it were either universally beneficial or inherently dangerous. Neither description adequately represents the evidence.

Systemic hormone therapy can substantially relieve vasomotor symptoms and may offer additional benefits for selected women. Its suitability depends on age, time since menopause, medical history, treatment formulation, route of administration, individual risk factors, and patient preferences.

For many otherwise healthy women with bothersome symptoms, the balance of benefits and risks may be favorable when treatment begins before age 60 or within approximately ten years of menopause onset, provided relevant contraindications are absent.

These considerations do not mean every woman in that age group should receive treatment. Nor do they establish that hormone therapy is always inappropriate later in life. Decisions require individualized assessment rather than a rule based solely on age.

The presence or absence of a uterus is important when selecting treatment. Women with an intact uterus receiving systemic estrogen generally require appropriate progestogen treatment to protect the endometrium. Women who have undergone total hysterectomy may have different treatment requirements.

A history of breast cancer, venous thromboembolism, stroke, cardiovascular disease, unexplained vaginal bleeding, or other relevant conditions can substantially affect treatment decisions. The risks associated with systemic hormone therapy also vary according to the specific hormones used, the route of administration, and individual clinical circumstances.

International recommendations in this area continue to evolve.

In February 2026, the United States Food and Drug Administration approved labeling changes for six menopausal hormone therapy products. Statements concerning cardiovascular disease, breast cancer, and probable dementia were removed from their boxed warnings. Information concerning cardiovascular and breast cancer risks remains in other parts of the prescribing information for relevant systemic products, while the boxed warning concerning endometrial cancer remains for systemic estrogen-only therapy.

These changes reflect a reassessment of how treatment risks should be communicated. They do not establish that the underlying risks have disappeared or that hormone therapy is appropriate for every woman. Clinical decisions still require consideration of the individual's circumstances and the specific treatment.

Another development occurred in September 2026, when the International Federation of Gynecology and Obstetrics and the World Heart Federation published a joint position paper addressing menopausal hormone therapy in women with cardiovascular risk factors or established ischemic heart disease.

The paper emphasizes individualized cardiovascular risk assessment and multidisciplinary care. It also discusses circumstances in which systemic hormone therapy may be considered for carefully selected women with established ischemic heart disease following assessment of benefits and risks, counseling, and shared decision-making.

This position requires particular attention in Viet Nam. The Ministry of Health's 2024 national menopause guidance lists coronary artery disease and myocardial ischemia among the contraindications to menopausal hormone therapy. The newer international position paper therefore should not be interpreted as automatically changing the Vietnamese guidance or authorizing treatment contrary to applicable local professional requirements.

For healthcare professionals in Viet Nam, decisions concerning menopausal hormone therapy must take account of the relevant Vietnamese guidance, authorized professional scope, product-specific requirements, and applicable law. Where international recommendations differ, the difference should be acknowledged explicitly rather than presented as a settled change in local clinical practice.

Hormone therapy should not be initiated solely for the primary prevention of cardiovascular disease or dementia in women experiencing menopause at the usual age. Although certain hormone regimens may benefit bone health, osteoporosis prevention and treatment require their own clinical risk assessment.

Lifestyle interventions remain relevant whether a woman receives hormone therapy or not. Appropriate nutrition, physical activity, sleep support, and avoidance of harmful substances can support overall health, but they do not eliminate medication risks or replace the clinical assessment required for hormone treatment.

Supplements, Herbal Products, and Claims About Hormone Balance

Women seeking relief from menopausal symptoms may encounter advertisements for supplements, herbal products, detoxification programs, and treatments described as restoring or balancing hormones.

Such claims should be evaluated carefully. A product described as natural is not necessarily effective or free from harm. Its composition, dose, manufacturing quality, possible interactions with medicines, and regulatory classification may all influence its suitability.

Phytoestrogens and isoflavones are frequently discussed in menopause care. These compounds occur naturally in certain plants and foods, including soy products. However, consuming foods containing phytoestrogens is not equivalent to using concentrated supplements as medical treatments.

There are differences between Vietnamese and international professional guidance in this area.

The Ministry of Health's 2024 national guideline includes phytoestrogen- and isoflavone-containing products among supportive nonhormonal approaches for certain menopausal symptoms. In contrast, The Menopause Society's 2023 evidence review did not recommend soy foods, soy extracts, or herbal supplements as established treatments for vasomotor symptoms because of insufficient or inconsistent evidence. The European Society of Endocrinology's 2025 guideline also describes the evidence concerning phytoestrogens as inconclusive.

The British Menopause Society's consensus statement on nonhormonal treatments, amended in July 2026, similarly emphasizes the importance of critically evaluating complementary and alternative approaches. Although some women may report individual benefits, few complementary interventions have sufficiently robust evidence to support confident treatment recommendations.

These differences should be understood in the context of each document's purpose, evidence-assessment methods, and the outcomes being considered.

A recommendation in national professional guidance should not be ignored, but neither should its inclusion be presented as proof that every listed intervention has equally strong supporting evidence.

For healthcare professionals, responsible counseling involves understanding what a product is intended to achieve, the quality of evidence for that outcome, its safety profile, and its regulatory status in Viet Nam.

The same principle applies to yoga, relaxation, mindfulness, and other supportive practices. These activities may contribute to well-being or help some women cope with symptoms without necessarily producing a reliable reduction in hot-flash frequency.

Particular caution is warranted when products or programs promise to restore ovarian function, prevent natural menopause, reverse hormonal aging, or eliminate the need for established medical treatment. Such claims require credible scientific evidence and should not be accepted merely because they are presented as natural or nonpharmacological approaches.

Early Menopause and Premature Ovarian Insufficiency Are Different Clinical Situations

Most women experience natural menopause during midlife, but some experience ovarian insufficiency or menopause substantially earlier.

Menopause occurring between the ages of 40 and 44 is commonly described as early menopause. Premature ovarian insufficiency refers to impaired ovarian activity before age 40, supported by appropriate clinical and biochemical assessment.

Premature ovarian insufficiency does not necessarily mean ovarian activity has ceased permanently in every case. Ovarian function can fluctuate, and spontaneous pregnancy remains possible in some women. Nevertheless, the condition can have important implications for fertility, bone health, cardiovascular health, sexual well-being, and psychological health.

The international evidence-based guideline on premature ovarian insufficiency, updated in 2024, emphasizes appropriate diagnosis, individualized care, and management of long-term health risks.

Hormone therapy is generally recommended for women with premature ovarian insufficiency until approximately the usual age of natural menopause, unless contraindicated. This recommendation differs from decisions about starting hormone therapy in women who have reached menopause at the usual age because the clinical objectives include addressing the consequences of estrogen deficiency occurring earlier than expected.

Lifestyle interventions remain valuable for overall health, but they cannot reliably restore normal ovarian function or replace appropriate medical management.

A woman younger than 40 who develops persistent menstrual irregularity, symptoms suggesting estrogen deficiency, or fertility concerns should therefore receive appropriate clinical assessment rather than being advised solely to exercise more, manage stress, or take supplements.

Menopause following surgery, chemotherapy, or other medical treatment may involve additional reproductive, medical, and psychological considerations requiring specialist expertise.

Reproductive counseling also remains relevant during perimenopause. Irregular menstrual cycles do not necessarily mean that pregnancy is no longer possible. Contraceptive needs should be discussed when appropriate to the woman's circumstances and preferences.

Long-Term Health Requires Individual Risk Assessment

Menopause care should extend beyond symptom relief. Midlife offers an opportunity to review cardiovascular risk, metabolic health, bone health, and other factors relevant to healthy aging.

Assessment may include blood pressure, glucose regulation, lipid disorders, smoking, physical activity, medical history, and other individual risk factors. Evidence-based lifestyle interventions can contribute to prevention and management, but they should not replace medication or other treatment when clinically indicated.

Bone health deserves attention because declining estrogen levels contribute to changes in bone metabolism and may increase the risk of osteoporosis and fractures. Appropriate physical activity, resistance training, adequate nutrition, and avoidance of tobacco can support musculoskeletal health.

However, these measures are not substitutes for osteoporosis assessment and treatment in women at elevated fracture risk. Decisions about bone density testing, fracture risk assessment, and medication should reflect the woman's clinical circumstances and applicable professional guidance.

Changes in body composition and abdominal fat distribution may also occur during the menopausal transition. These changes should not automatically be attributed to hormones alone. Aging, physical activity, dietary patterns, sleep, medications, genetics, and other factors contribute.

The objective is not to interpret every change in midlife as a medical problem requiring investigation or treatment. It is to identify relevant risks, provide proportionate preventive care, and recognize when further assessment may improve health outcomes.

This also means avoiding an excessive focus on body weight as the only meaningful outcome. Strength, physical capacity, cardiometabolic health, nutritional adequacy, and quality of life may be equally or more relevant to an individual woman's priorities.

When Symptoms Should Not Be Attributed to Menopause Alone

Menopause can explain many symptoms, but it should not become a convenient explanation for every health concern arising during midlife.

Abnormal vaginal bleeding is an important example. Heavy, persistent, or unusual bleeding during perimenopause may require investigation. Bleeding after menopause should not automatically be regarded as a normal hormonal change.

The National Institute for Health and Care Excellence updated its menopause guideline in April 2026 to clarify recommendations concerning unscheduled vaginal bleeding in women receiving systemic hormone therapy.

For women with a uterus, some vaginal bleeding can occur during the first six months of systemic hormone therapy or within three months of changing the dose or preparation. The guideline advises seeking medical help promptly when unscheduled bleeding occurs beyond these periods. Earlier assessment may also be necessary when bleeding is heavy, persistent, or accompanied by other concerning findings.

These recommendations concern bleeding associated with systemic hormone therapy and should not be confused with the assessment of postmenopausal bleeding in women who are not receiving such treatment.

The recommendations provide useful clinical context but do not replace applicable Vietnamese guidance or individualized medical judgment. Persistent or concerning bleeding warrants appropriate assessment rather than reassurance based solely on menopausal status or hormone treatment.

Other symptoms may also require investigation. Persistent pelvic pain, unexplained weight loss, significant urinary complaints, severe mood symptoms, or new symptoms inconsistent with the expected clinical picture should not be dismissed.

Palpitations, fatigue, sleep disturbance, and difficulties with concentration can sometimes be associated with menopause, but they may also indicate thyroid disease, cardiovascular conditions, sleep disorders, depression, or other medical problems.

A diagnosis of menopause should not delay the recognition or treatment of another condition. Appropriate preventive screening and general healthcare should also continue after menopause according to age, individual risk factors, medical history, and relevant national guidance.

What Recent Research in Viet Nam Suggests

Research concerning menopause in Viet Nam is developing, although the available evidence should be interpreted according to the populations studied and the methods used.

A cross-sectional study involving 403 female healthcare workers aged 40–60 at Hung Vuong Hospital in Ho Chi Minh City examined knowledge, attitudes, and practices related to perimenopause and menopause. The survey was conducted between March and June 2024 and published online on February 4, 2026, in Przegląd Menopauzalny.

The researchers reported that 73.5% of participants met the study's criteria for good knowledge, 65.3% demonstrated positive attitudes, and 39.7% met the criteria for good practices.

The findings suggest that knowledge, attitudes, and the practices assessed by the study were not always aligned. Understanding menopause did not necessarily mean that all recommended behaviors were consistently reported.

However, these results have important limitations. The study involved female healthcare workers at one hospital, used a cross-sectional design, and relied on questionnaire responses. It cannot establish the prevalence of menopausal symptoms among Vietnamese women, the effectiveness of specific treatments, or the quality of menopause care nationally.

The findings nevertheless raise questions relevant to professional education. How well do healthcare professionals understand the available treatment options? Can they distinguish interventions supported by strong evidence from those with uncertain benefits? Do women know when to seek clinical assessment for symptoms that affect their daily lives?

These questions extend beyond individual knowledge. Access to suitable care, time, financial resources, and the availability of appropriately trained clinicians may influence whether women receive assessment and treatment.

More diverse Vietnamese research could help clarify women's experiences, care-seeking behaviors, treatment access, and health outcomes across different healthcare settings and communities.

Research examining not only what women know about menopause but also how they obtain care and experience treatment would be particularly valuable.

Making Menopause Care More Accessible and Respectful

Women may face different barriers when seeking care for menopausal symptoms.

Some may consider vaginal discomfort or sexual concerns too personal to discuss. Others may be uncertain whether their symptoms require treatment or may have difficulty accessing clinicians with relevant expertise. Employment, family responsibilities, financial circumstances, and the availability of healthcare services may also influence their decisions.

These circumstances should not lead to unsupported assumptions about all Vietnamese women. Experiences and preferences vary considerably.

An appropriate care pathway may begin with a primary care clinician or another qualified healthcare professional. More complex concerns may require assessment by an obstetrician-gynecologist, endocrinologist, mental health professional, or another appropriately qualified specialist.

Care should support informed decisions. Women need understandable information about the expected benefits, limitations, and risks of available treatments, including lifestyle-related interventions, hormone therapy, and nonhormonal approaches.

They should also have opportunities to discuss their preferences, previous experiences, and concerns. For one woman, relief from severe night sweats may be the immediate priority. Another may be more concerned about bone health, sexual discomfort, cardiovascular risk, or the implications of early menopause.

The involvement of partners or family members may be helpful when the woman wishes it, but such support should not replace her preferences, privacy, and lawful rights.

Responsible Lifestyle Medicine must also recognize that healthy behaviors are influenced by circumstances beyond individual motivation. Access to nutritious food, safe places for physical activity, sufficient time for sleep, and appropriate healthcare services is not equal for everyone.

The 2025 update of the Lifestyle Medicine Core Competencies reinforces the importance of social determinants of health and the need to adapt interventions to people's circumstances. This principle is relevant to menopause care because even scientifically sound recommendations may be difficult to follow when they do not reflect the realities of an individual's life.

The aim is care that is evidence-informed, clinically appropriate, practical, and respectful of the person receiving it.

What This Means for the Vietnam Lifestyle Medicine Alliance

Menopause provides an example of how Lifestyle Medicine can contribute to healthcare without claiming to replace established clinical treatment.

The challenge is not simply to encourage healthier behaviors. It is to understand which interventions improve general health, which have demonstrated effectiveness for specific menopausal symptoms, and when additional clinical care is necessary.

For VLMA, professional education and scientific knowledge exchange could help healthcare professionals interpret these distinctions. Relevant topics include the menopausal transition, the evidence for lifestyle-related interventions, the recognition of symptoms requiring assessment, the relationship between menopause and long-term health, and the responsible interpretation of international recommendations within the Vietnamese healthcare context.

These areas also create opportunities for interdisciplinary collaboration. Obstetrician-gynecologists, endocrinologists, primary care physicians, dietitians, mental health professionals, and other appropriately qualified practitioners bring different expertise to women's midlife health.

As VLMA develops, such collaboration could strengthen the quality of educational resources and support more informed professional discussions about the place of Lifestyle Medicine in comprehensive menopause care.

VLMA's contribution should remain aligned with its role as a physician-led professional platform. Potential educational and collaborative activities do not imply that VLMA currently provides menopause consultations, specialist clinical services, hormone treatment, or individualized medical care.

Clinical examination, diagnosis, prescription, treatment, and follow-up remain the responsibilities of appropriately authorized healthcare professionals and facilities acting within their lawful professional scopes.

Maintaining these boundaries is important for the credibility of Lifestyle Medicine. Scientific evidence should inform professional education and clinical understanding, while treatment decisions remain grounded in individual assessment, relevant professional guidance, and applicable legal requirements.

Supporting Health Without Overpromising

Menopause is a significant life transition, but it is not a single condition with one solution. Some women need little intervention beyond reliable information and preventive healthcare. Others experience symptoms that require specific treatment, while some have underlying conditions or health risks that need attention independently of menopause.

Lifestyle Medicine can contribute to long-term health through appropriate nutrition, physical activity, restorative sleep, stress management, tobacco avoidance, and positive social connections. These approaches remain valuable whether or not a woman experiences substantial menopausal symptoms.

However, their benefits should not be overstated. General improvements in health do not automatically establish effectiveness for hot flashes, genitourinary symptoms, or other specific menopausal concerns.

Hormonal and nonhormonal treatments also have established roles, with benefits, risks, and limitations that require individualized professional assessment.

For healthcare professionals in Viet Nam, responsible menopause care involves understanding national guidance, remaining informed about international evidence, recognizing differences in the strength of recommendations, and helping women make informed decisions about their health.

The value of Lifestyle Medicine during menopause lies in supporting long-term health and well-being while recognizing when specific, evidence-based clinical treatment is needed.

Healthy living should be encouraged throughout the menopausal transition and beyond. It is an important part of comprehensive healthcare, not a reason to delay necessary assessment or treatment.

For VLMA, advancing this balanced understanding is one way to support evidence-based Lifestyle Medicine responsibly in Viet Nam.

Selected References

1. Ministry of Health of Viet Nam. Decision No. 3977/QĐ-BYT Issuing the National Guidelines for Reproductive Health Care Services: Health Care for Women During Perimenopause and Menopause. December 30, 2024. Effective December 30, 2024. Replaced Decision No. 3793/QĐ-BYT dated December 17, 2024.

2. World Health Organization. Menopause. Fact sheet. October 16, 2024.

3. Lumsden MA, Dekkers OM, Faubion SS, et al. European Society of Endocrinology Clinical Practice Guideline for Evaluation and Management of Menopause and the Perimenopause. European Journal of Endocrinology. 2025;193(4)–G81. doi:10.1093/ejendo/lvaf206.

4. National Institute for Health and Care Excellence. Menopause: Identification and Management. NICE Guideline NG23. Originally published November 12, 2015. Updated April 15, 2026, with a minor editorial correction in August 2026.

5. Panay N, Fenton A, Hamoda H, et al. International Menopause Society Recommendations and Key Messages on Women's Midlife Health and Menopause. Climacteric. 2025;28(6):634–656. doi:10.1080/13697137.2025.2585487. See also the updated recommendations released by the International Menopause Society in March 2026.

6. Correction: International Menopause Society Recommendations and Key Messages on Women's Midlife Health and Menopause. Climacteric. 2026;29(2):318–320. doi:10.1080/13697137.2026.2638063.

7. The North American Menopause Society. The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society. Menopause. 2023;30(6):573–590. doi:10.1097/GME.0000000000002200.

8. The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2022;29(7):767–794. doi:10.1097/GME.0000000000002028.

9. British Menopause Society. Non-hormonal-based Treatments for Menopausal Symptoms. Consensus statement. Reviewed November 2025; amended July 2026.

10. National Institute for Health and Care Excellence. Fezolinetant for Treating Moderate to Severe Vasomotor Symptoms Associated With Menopause. Technology Appraisal Guidance TA1143. March 31, 2026.

11. United States Food and Drug Administration. Drug Trials Snapshots: Lynkuet (Elinzanetant). Approved October 24, 2025.

12. United States Food and Drug Administration. FDA Adds Warning About Rare Occurrence of Serious Liver Injury With Use of Veozah (Fezolinetant) for Hot Flashes Due to Menopause. Drug Safety Communication. Updated December 16, 2024.

13. United States Food and Drug Administration. FDA Approves Labeling Changes to Menopausal Hormone Therapy Products. February 12, 2026.

14. Benedetto C, Gulati M, Khadilkar SS, et al. Menopause Hormone Therapy in Women With Cardiovascular Risk Factors or Established Ischemic Heart Disease: A Joint FIGO and WHF Position Paper. International Journal of Gynecology & Obstetrics. Published online September 22, 2026. doi:10.1002/ijgo.71356.

15. Panay N, Anderson RA, Bennie A, et al. Evidence-Based Guideline: Premature Ovarian Insufficiency. Human Reproduction Open. 2024;2024(4). doi:10.1093/hropen/hoae065.

16. Huynh TNK, Nguyen NT, Huynh PN, et al. Knowledge, Attitudes, and Practices on Menopause Among Female Health Workers in Vietnam: Findings From a Cross-Sectional Study. Przegląd Menopauzalny. 2025;24(4):268–281. Published online February 4, 2026. doi:10.5114/pm.2025.158469.

17. Rea BL, Cheema S, Lanza S, et al. Lifestyle Medicine Core Competencies: 2025 Update. American Journal of Lifestyle Medicine. 2026;20(3):443–451. First published online October 28, 2025. doi:10.1177/15598276251379821.

18. National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. January 9, 2023. Effective January 1, 2024, as amended. See Consolidated Document No. 26/VBHN-VPQH dated February 26, 2026.

Editorial and Professional Scope Note

This article presents an educational and professional perspective of the Vietnam Lifestyle Medicine Alliance on the contribution and limitations of evidence-based Lifestyle Medicine during perimenopause and menopause, based on information reviewed through October 30, 2026. It is intended for professional education, scientific knowledge exchange, and general information.

This article is not a clinical practice guideline, individualized medical advice, a diagnosis, a treatment protocol, a prescription, or an authoritative interpretation of Vietnamese law. References to international guidelines, medications, and treatment options are provided for educational purposes and do not establish their regulatory approval, clinical availability, or authorization for use in Viet Nam.

VLMA is a physician-led professional platform operated by Vietnam Lifestyle Medicine Alliance Company Limited. It is not a licensed medical examination or treatment facility and does not independently provide menopause consultations, prescribe hormonal or nonhormonal treatments, perform clinical screening, or offer individualized menopause care.

Clinical assessment, diagnosis, prescribing, treatment, screening, and follow-up must be undertaken by appropriately authorized healthcare professionals and facilities within their lawful scopes of practice, taking account of individual clinical circumstances, applicable Vietnamese professional guidance, relevant scientific evidence, and legal requirements.

Lifestyle-related interventions should not delay or replace necessary medical assessment, indicated treatment, investigation of abnormal bleeding, or appropriate specialist care. The inclusion of a treatment or professional framework in this article does not imply that VLMA has formally adopted, clinically implemented, validated, or certified it.